GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (FRA:TKDA) » Definitions » Beta

Takeda Pharmaceutical Co (FRA:TKDA) Beta : 0.25 (As of Dec. 13, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Takeda Pharmaceutical Co Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-12-13), Takeda Pharmaceutical Co's Beta is 0.25.


Takeda Pharmaceutical Co Beta Historical Data

The historical data trend for Takeda Pharmaceutical Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Beta Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.56 0.49 0.09

Takeda Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.17 0.09 0.14 0.20

Competitive Comparison of Takeda Pharmaceutical Co's Beta

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co's Beta Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Beta distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Beta falls into.



Takeda Pharmaceutical Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Takeda Pharmaceutical Co  (FRA:TKDA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Takeda Pharmaceutical Co Beta Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Takeda Pharmaceutical Co Business Description

Address
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co Headlines

No Headlines